[Prostatic high resolution micro-ultrasound (MUS) imaging.]
Prostate cancer (PCa) diagnosis has improved with multiparametric magnetic resonance (mpMRI) and new more specific biomarkers. However, mpMRI has some limitations such as variability, long learning curve and high cost. More progress is needed in the PCa diagnosis scenario, and it is here where high resolution micro-ultrasound (MUS) imaging system emerge. Retrospective study between February (2017-2018); including 96 patients with PCa suspicion, undergoing transrectal prostate biopsy guided by MUS. Procedure was performed by 2 urologists blinded to mpMRI results at first (92% available). PRI-MUS protocol was used to identify suspicious features. 2 core targeted biopsy of suspicious areas (PRIMUS >3) was completed first and then it was followed by a 12-core systematic biopsy and finally sampling of mpMRI targets if available. Data were collected reporting sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) to detect clinically significant PCa (csPCa) (Gleason score >7). Overall, MUS csPCa detection rate was 59.37%. 171 cores were registered, of them csPCa were distributed as follow: 1.2% PRI-MUS 1, 16.3% PRIMUS 2, 28% PRI-MUS 3, 39% PRI-MUS 4 and 15% PRI-MUS 5. Sensitivity in csPCa detection for PRI-MUS >3 was 82% with 93% NPV, but with low 39% specificity and 19% PPV. Comparing 79 patients with mpMRI available; sensitivity by area of MUS was 82% versus 30% of mpMRI, with 93% NPV versus 88%. Specificity and PPV were higher in mpMRI in comparison to MUS. Although this is a preliminary series, MUS is presented as an attractive imaging technique, cost-effective, easy to learn and with high efficacy in image- guided prostate biopsy. Overall PCa detection rate increases over conventional ultrasound; and offers high sensitivity and NPV in csPCa detection over mpMRI but with lower specificity.